Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract.


Journal

Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 24 01 2020
accepted: 13 02 2020
pubmed: 29 2 2020
medline: 29 5 2020
entrez: 29 2 2020
Statut: ppublish

Résumé

To examine the effect of conditional survival on 5-year cancer-specific survival (CSS) probability after radical nephroureterectomy (RNU) in a contemporary cohort of patients with non-metastatic urothelial carcinoma of the upper urinary tract (UTUC). Within the Surveillance, Epidemiology and End Results database (2004-2015), 6826 patients were identified. Conditional 5-year CSS estimates were assessed after event-free follow-up duration. Multivariable Cox regression (MCR) models predicted cancer-specific mortality (CSM) according to event-free follow-up length. Overall, 956 (14.0%) were T A direct relationship exists between event-free follow-up and survival probability after RNU. From a clinical perspective, such survival estimates may have particular importance during preoperative counseling.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
To examine the effect of conditional survival on 5-year cancer-specific survival (CSS) probability after radical nephroureterectomy (RNU) in a contemporary cohort of patients with non-metastatic urothelial carcinoma of the upper urinary tract (UTUC).
METHODS METHODS
Within the Surveillance, Epidemiology and End Results database (2004-2015), 6826 patients were identified. Conditional 5-year CSS estimates were assessed after event-free follow-up duration. Multivariable Cox regression (MCR) models predicted cancer-specific mortality (CSM) according to event-free follow-up length.
RESULTS RESULTS
Overall, 956 (14.0%) were T
CONCLUSIONS CONCLUSIONS
A direct relationship exists between event-free follow-up and survival probability after RNU. From a clinical perspective, such survival estimates may have particular importance during preoperative counseling.

Identifiants

pubmed: 32107785
doi: 10.1002/jso.25877
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1154-1161

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. https://doi.org/10.3322/caac.20138
Hurle R, Colombo P, Lazzeri M, et al. Pathological outcomes for patients who failed to remain under active surveillance for low-risk non-muscle-invasive bladder cancer: update and results from the bladder cancer Italian active surveillance project. Eur Urol Oncol. 2018;1:437-442. https://doi.org/10.1016/j.euo.2018.05.006
Weiner AB, Desai AS, Meeks JJ. Tumor location may predict adverse pathology and survival following definitive treatment for bladder cancer: a national cohort study. Eur Urol Oncol. 2019;2:304-310. https://doi.org/10.1016/j.euo.2018.08.018
Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111-122. https://doi.org/10.1016/j.eururo.2017.07.036
Shigeta K, Kikuchi E, Abe T, et al. A novel risk-based approach simulating oncological surveillance after radical nephroureterectomy in patients with upper tract urothelial carcinoma. Eur Urol Oncol. 2019;30. In press. https://doi.org/10.1016/j.euo.2019.06.021
Fairey AS, Kassouf W, Estey E, et al. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU Int. 2013;112:791-797. https://doi.org/10.1111/j.1464-410X.2012.11474.x
Gandaglia G, Bianchi M, Trinh Q-D, et al. Survival after nephroureterectomy for upper tract urothelial carcinoma: a population-based competing-risks analysis. Int J Urol. 2014;21:249-256. https://doi.org/10.1111/iju.12267
Li C-C, Chang T-H, Wu W-J, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol. 2008;54:1127-1135. https://doi.org/10.1016/j.eururo.2008.01.054
Rouprêt M, Hupertan V, Seisen T, et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol. 2013;189:1662-1669. https://doi.org/10.1016/j.juro.2012.10.057
Skuladottir H, Olsen JH. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3035-3040. https://doi.org/10.1200/JCO.2003.04.521
Ploussard G, Shariat SF, Dragomir A, et al. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol. 2014;66:361-370. https://doi.org/10.1016/j.eururo.2013.09.050
Hieke S, Kleber M, Konig C, Engelhardt M, Schumacher M. Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res. 2015;21:1530-1536. https://doi.org/10.1158/1078-0432.CCR-14-2154
Palumbo C, Mistretta FA, Knipper S, et al. How cancer-specific mortality changes over time after radical cystectomy: conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. Urol Oncol. 2019;37:893-899. https://doi.org/10.1016/j.urolonc.2019.05.020
Mistretta FA, Palumbo C, Knipper S, et al. Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. World J Urol. 2019. In press. https://doi.org/10.1007/s00345-019-02869-6
Ploussard G, Xylinas E, Lotan Y, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol. 2015;67:803-812. https://doi.org/10.1016/j.eururo.2014.08.003
Kang M, Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Conditional survival and associated prognostic factors in patients with upper tract urothelial carcinoma after radical nephroureterectomy: a retrospective study at a single institution. Cancer Res Treat. 2016;48:621-631. https://doi.org/10.4143/crt.2015.220
Kim E, Kim JS, Choi M, Thomas CR. Conditional survival in anal carcinoma using the national population-based survey of epidemiology and end results database (1988-2012). Dis Colon Rectum. 2016;59:291-298. https://doi.org/10.1097/DCR.0000000000000555
Zhang G, Li R, Deng Y, Zhao L. Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol. 2018;12:515-523. https://doi.org/10.1080/17474124.2018.1453806
Zhong Q, Chen Q-Y, Xie J-W, et al. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Cancer Med. 2018;7:3521-3533. https://doi.org/10.1002/cam4.1598

Auteurs

Giuseppe Rosiello (G)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Carlotta Palumbo (C)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.

Sophie Knipper (S)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Angela Pecoraro (A)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Department of Urology,San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.

Stefano Luzzago (S)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Department of Urology, European Institute of Oncology, Milan, Italy.

Marina Deuker (M)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.

Francesco A Mistretta (FA)

Department of Urology, European Institute of Oncology, Milan, Italy.

Zhe Tian (Z)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.

Nicola Fossati (N)

Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Andrea Gallina (A)

Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Francesco Montorsi (F)

Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Institute of Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.

Fred Saad (F)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.

Alberto Briganti (A)

Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH